Literature DB >> 27630853

Effectiveness of Pooled Platelet Transfusion in Concordant and Discordant Groups among Dengue Patients.

Amoolya Bhat1, Vijaya Chowdappa2, Smita Surendra Masamatti1.   

Abstract

INTRODUCTION: Dengue affects more than 50 million people per year and is one of the most common causes of severe thrombocytopaenia. Thrombocytopaenia is a common complication of dengue and other viral fevers apart from malaria, typhoid, leptospirosis, leukaemia and megaloblastic anaemia. A platelet count of <20,000/μl is characteristically seen in dengue haemorrhagic fever and dengue fever. It results from immune complex mediated platelet destruction or bone marrow suppression. Severe thrombocytopaenia <10,000/μl is one of the indications for prophylactic platelet transfusion therapy to prevent haemorrhage. AIM: To evaluate the effectiveness of transfusion of ABO compatible and ABO incompatible pooled platelet units in severe thrombocytopaenia cases.
MATERIALS AND METHODS: In this study ABO compatible and incompatible pooled platelet units were transfused to serologically confirmed dengue cases having thrombocytopaenia with or without bleeding manifestations. Each of the adult patients received 4-6 units of pooled platelet concentrates prepared from random donor whole blood suspended in plasma for severe thrombocytopaenia. Pre and post transfusion platelet counts were compared. Children aged less than 12 years, pregnant women and patients with splenomegaly those on ayurvedic and homeopathic therapy, recipients of packed red cells on the same day of platelet transfusion and recipients of multiple platelet transfusions within 24 hours were excluded from the study.
RESULTS: The median post transfusion platelet increments (PPI) and corrected count increments (CCI) at 4hour post transfusion were 25,000/μL (5,000-80,000/μL) and 18,000/μL (range 8,000/μL- 47,500/μL) respectively among the responders. Median PPI and CCI at 24 hours were 45,000/μL and 28,863/μL among the responders. The median CCI at 4 hour post transfusion among the non-responders was 850/μL and at 24hours was 1,425/μL. At 24 hours responders showed significantly higher PPI as compared to non responders. The average platelets transfused were 4units in case of responders and 8 units in case of non-responders.
CONCLUSION: ABO identical and compatible pooled platelet transfusions were more successful in increasing the post transfusion platelet counts as compared to ABO incompatible pooled platelets.

Entities:  

Keywords:  ABO compatible; ABO identical; Dengue; Platelet transfusion; Pooled

Year:  2016        PMID: 27630853      PMCID: PMC5020224          DOI: 10.7860/JCDR/2016/19278.8213

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Anti-A and anti-B titers in pooled group O platelets are comparable to apheresis platelets.

Authors:  Laura L Cooling; Theresa A Downs; Suzanne H Butch; Robertson D Davenport
Journal:  Transfusion       Date:  2008-07-09       Impact factor: 3.157

2.  Platelet transfusion - the art and science of compromise.

Authors:  Joan Cid; Sarah K Harm; Mark H Yazer
Journal:  Transfus Med Hemother       Date:  2013-04-26       Impact factor: 3.747

3.  Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs.

Authors:  Friedgard Julmy; Roland A Ammann; Behrouz Mansouri Taleghani; Stefano Fontana; Andreas Hirt; Kurt Leibundgut
Journal:  Transfusion       Date:  2008-09-04       Impact factor: 3.157

4.  Platelet transfusion and survival in adults with acute leukemia.

Authors:  N Blumberg; J M Heal; J L Liesveld; G L Phillips; J M Rowe
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

5.  Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study.

Authors:  Katerina Pavenski; Theodore E Warkentin; Hua Shen; Yang Liu; Nancy M Heddle
Journal:  Transfusion       Date:  2010-02-26       Impact factor: 3.157

6.  Leukocyte-reduced transfusions of ABO-identical platelets and clinical outcome in autologous bone marrow transplantation for lymphoma.

Authors:  J M Heal; N Blumberg; S A Kirkley; J F DiPersio; A P Rapoport; J M Rowe
Journal:  Bone Marrow Transplant       Date:  1994-12       Impact factor: 5.483

7.  Platelet use in pediatric oncology: a review of 393 transfusions.

Authors:  J van Eys; D Thomas; B Olivos
Journal:  Transfusion       Date:  1978 Mar-Apr       Impact factor: 3.157

8.  The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.

Authors:  Darrell J Triulzi; Susan F Assmann; Ronald G Strauss; P M Ness; John R Hess; Richard M Kaufman; Suzanne Granger; Sherrill J Slichter
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

9.  Dose of prophylactic platelet transfusions and prevention of hemorrhage.

Authors:  Sherrill J Slichter; Richard M Kaufman; Susan F Assmann; Jeffrey McCullough; Darrell J Triulzi; Ronald G Strauss; Terry B Gernsheimer; Paul M Ness; Mark E Brecher; Cassandra D Josephson; Barbara A Konkle; Robert D Woodson; Thomas L Ortel; Christopher D Hillyer; Donna L Skerrett; Keith R McCrae; Steven R Sloan; Lynne Uhl; James N George; Victor M Aquino; Catherine S Manno; Janice G McFarland; John R Hess; Cindy Leissinger; Suzanne Granger
Journal:  N Engl J Med       Date:  2010-02-18       Impact factor: 91.245

10.  Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial.

Authors:  Muhammad Zaman Khan Assir; Umair Kamran; Hafiz Ijaz Ahmad; Sadia Bashir; Hassan Mansoor; Saad Bin Anees; Javed Akram
Journal:  Transfus Med Hemother       Date:  2013-09-11       Impact factor: 3.747

View more
  1 in total

1.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.